Literature DB >> 28132132

Impaired Vascular Function in Sarcoidosis Patients.

I Tuleta1, D Skowasch2, L Biener2, C Pizarro2, R Schueler2, G Nickenig2, N Schahab2, C Schaefer2, S Pingel2.   

Abstract

A common feature of sarcoidosis and atherosclerosis is a chronic systemic inflammatory reaction. Our hypothesis was that sarcoidosis may negatively influence the vessel status. We addressed the issue by examining preatherosclerotic vascular alternations using an ultrasound-based speckle-tracking method in 72 sarcoidosis patients and 15 matched controls. To find potential factors which may have a deleterious influence on arterial performance, different subgroups of sarcoidosis, such as sarcoidosis with or without cortisone therapy, pulmonary sarcoidosis in early and advanced stages, pulmonary sarcoidosis alone or combined with extrapulmonary sarcoidosis, and sarcoidosis with or without elevated blood levels of angiotensin converting enzyme (ACE)/soluble interleukin 2 receptor (sIL-2R) were investigated. We found in the general collective of sarcoidosis patients that circumferential strain (2.68 ± 0.19%), circumferential strain rate (0.21 ± 0.01 1/s), and radial displacement (0.10 ± 0.01 mm) were significantly decreased compared to controls (3.77 ± 0.35%, 0.28 ± 0.02 1/s, and 0.14 ± 0.02 mm, respectively). Vascular strains were more impaired in patients with cortisone therapy, pulmonary sarcoidosis in stages III-IV, and in pulmonary sarcoidosis accompanied by extrapulmonary involvement. The level of ACE/sIL-2R had no relevant influence on the angiological parameters. In conclusion, sarcoidosis is associated with increased vascular stiffness. Cortisone therapy and advanced stages of pulmonary sarcoidosis with extrapulmonary manifestations may account for the impaired vascular function in this patient collective.

Entities:  

Keywords:  Arterial Elastic Properties; Atherosclerosis; Granulomatous Disease; Inflammation; Sarcoidosis Vasculopathy; Vascular Ultrasound

Mesh:

Substances:

Year:  2017        PMID: 28132132     DOI: 10.1007/5584_2016_203

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Association between sarcoidosis, pulse wave velocity, and other measures of subclinical atherosclerosis: a systematic review and meta-analysis.

Authors:  Wai Chung Yong; Anawin Sanguankeo; Sikarin Upala
Journal:  Clin Rheumatol       Date:  2017-11-25       Impact factor: 2.980

2.  Sarcoidosis of the paranasal sinuses.

Authors:  Thorsten Send; Izabela Tuleta; Tim Koppen; Thore Thiesler; Klaus W Eichhorn; Mattis Bertlich; Friedrich Bootz; Mark Jakob
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-21       Impact factor: 2.503

3.  Association between sarcoidosis and cardiovascular Outcomes: A systematic review and Meta-analysis.

Authors:  Vikash Jaiswal; Song Peng Ang; Zouina Sarfraz; Swatika Butey; Harshwardhan Vinod Khandait; David Song; Jia Ee Chia; Dipansha Maroo; Muhammad Hanif; Mohammed Ghanim; Raja Chand; Monodeep Biswas
Journal:  Int J Cardiol Heart Vasc       Date:  2022-06-29

4.  YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.

Authors:  Pelin Uysal; Sinem Durmus; Volkan Sozer; Remise Gelisgen; Ekrem Cengiz Seyhan; Fusun Erdenen; Gonul Simsek; Hafize Uzun
Journal:  Biomolecules       Date:  2018-08-28

5.  Microvascular capillaroscopic abnormalities and occurrence of antinuclear autoantibodies in patients with sarcoidosis.

Authors:  Francesco Cattelan; Elvis Hysa; Emanuele Gotelli; Carmen Pizzorni; Pietro Francesco Bica; Marco Grosso; Emanuela Barisione; Sabrina Paolino; Luca Carmisciano; Alberto Sulli; Vanessa Smith; Maurizio Cutolo
Journal:  Rheumatol Int       Date:  2022-08-30       Impact factor: 3.580

6.  Atherogenic Indices Can Predict Atherosclerosis in Patients with Sarcoidosis.

Authors:  Okan Selendili; Ersin Günay; Emre Kaçar; Şule Çilekar; Gürhan Öz; Ahmet Dumanli; Sibel Günay
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-01-13       Impact factor: 1.803

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.